Роль и место лозартана в сердечно-сосудистом континууме
Роль и место лозартана в сердечно-сосудистом континууме
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Список литературы
1. 2003 European Society of hypertension – European Society of cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53.
2. Whitworth JA, Chalmers J. World health organisation-international society of hypertension (WHO/ISH) hypertension guidelines. Clin Exp Hypertens 2004; 26 (7): 747–52.
3. Чазов Е.И., Беленков Ю.Н., Борисова Е.О., Гогин Е.Е. и др. Рациональная фармакотерапия сердечно-сосудистых заболеваний. Руководство для практикующих врачей. Под общ. ред. Е.И.Чазова, Ю.Н.Беленкова. М.: Литтерра, 2004.
4. Spinar J, Soueek M, Vitovec J. Kardiologicka revue 2002; 4: 225–30.
5. Clin Pharmacokinet 2005; 44 (8): 797–814.
6. Flammer AJ, Hermann F, Wiesli P et al. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. J Hypertens. 2007; 25 (4): 785–91.
7. Wachtell K, Okin PM, Olsen MH et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation. 2007; 116 (7): 700–5.
8. Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol 2007; 2 (3): 581–90.
9. Olsen MH, Fossum E, Hoieggen A et al. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens. 2005; 23 (4): 891–8.
10. Brenner BM, Cooper ME, De Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–9.
11. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349 (9054): 747–52.
12. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355 (9215): 1582–7.
13. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360 (9335): 752–60.
14. Sosa-Canache B, Hernandez-Hernandez R, Armas-Padilla MC et al. Effect of losartan therapy on endothelial function in hypertensive patients. Am J Ther 2007; 14 (2): 166–71.
15. Clin Therap 1998; 20: 978–89.
16. Shahinfar S, Simpson R, Carides A et al. Safety of losartan in hypertensive patients with asymptomatic hyperuricemia. JASN, 1997; 8: 322.
17. Dawson J, Quinn T, Walters M. Uric acid reduction: a new paradigm in the management of cardiovascular risk? Curr Med Chem 2007; 14 (17): 1879–86.
2. Whitworth JA, Chalmers J. World health organisation-international society of hypertension (WHO/ISH) hypertension guidelines. Clin Exp Hypertens 2004; 26 (7): 747–52.
3. Чазов Е.И., Беленков Ю.Н., Борисова Е.О., Гогин Е.Е. и др. Рациональная фармакотерапия сердечно-сосудистых заболеваний. Руководство для практикующих врачей. Под общ. ред. Е.И.Чазова, Ю.Н.Беленкова. М.: Литтерра, 2004.
4. Spinar J, Soueek M, Vitovec J. Kardiologicka revue 2002; 4: 225–30.
5. Clin Pharmacokinet 2005; 44 (8): 797–814.
6. Flammer AJ, Hermann F, Wiesli P et al. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. J Hypertens. 2007; 25 (4): 785–91.
7. Wachtell K, Okin PM, Olsen MH et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation. 2007; 116 (7): 700–5.
8. Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol 2007; 2 (3): 581–90.
9. Olsen MH, Fossum E, Hoieggen A et al. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens. 2005; 23 (4): 891–8.
10. Brenner BM, Cooper ME, De Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–9.
11. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349 (9054): 747–52.
12. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355 (9215): 1582–7.
13. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360 (9335): 752–60.
14. Sosa-Canache B, Hernandez-Hernandez R, Armas-Padilla MC et al. Effect of losartan therapy on endothelial function in hypertensive patients. Am J Ther 2007; 14 (2): 166–71.
15. Clin Therap 1998; 20: 978–89.
16. Shahinfar S, Simpson R, Carides A et al. Safety of losartan in hypertensive patients with asymptomatic hyperuricemia. JASN, 1997; 8: 322.
17. Dawson J, Quinn T, Walters M. Uric acid reduction: a new paradigm in the management of cardiovascular risk? Curr Med Chem 2007; 14 (17): 1879–86.
Авторы
О.Н.Ткачева, Н.К.Рунихина, И.М.Новикова,Н.В.Шарашкина
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.